ProfileGDS5678 / 1421018_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 82% 83% 80% 81% 83% 79% 81% 82% 84% 85% 85% 82% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.026983
GSM967853U87-EV human glioblastoma xenograft - Control 26.0479982
GSM967854U87-EV human glioblastoma xenograft - Control 36.0214983
GSM967855U87-EV human glioblastoma xenograft - Control 45.8381680
GSM967856U87-EV human glioblastoma xenograft - Control 55.8595781
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8637283
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3929679
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8186981
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9662982
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1901784
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.292285
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3730485
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8950782
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2546484